Angermann R, et al. - In patients receiving treatment with anti-vascular endothelial growth factor (VEGF) under universal health coverage, researchers assessed loss to follow-up (LTFU) rates between patients with diabetic retinopathy (DR), a major cause of vision impairment in advanced diabetes mellitus patients, vs those with neovascular age-related macular degeneration (nAMD). The study sample consisted of 1,264 patients receiving anti-VEGF therapy. For individuals with DR and nAMD, the LTFU rate was 28.8% and 2.9%, respectively, for at least 6 months. Despite treatment under universal health coverage, authors discovered a high long-term LTFU rate for patients with DR. Considering the risk of disease progression, especially in patients with chronic DR, approaches for improved compliance and adherence to therapy for optimized patient care should be considered. For LTFU beyond 12 months, advanced age, lack of mobility, and need for assisted transport, poor final visual acuity despite treatment, and decrease in vision during the observational period were independent risk factors, according to multivariate regression analysis.